Bulk formulation of a cattle and water buffalo anthrax spore vaccine from the Anthrax Spore Vaccine, Live (Strain II) Veterinary Grade API begins with reconstitution and normalization of the lyophilized spore powder against a batch-specific certificate of analysis. A representative powder count of 5.0 × 10⁹ CFU/g requires an addition ratio of 0.20% w/v into a chilled phosphate-buffered saline diluent containing 20% v/v glycerin to bring the final suspension to 1.0 × 10⁷ CFU/mL; if the API lot falls to 2.0 × 10⁹ CFU/g, the addition ratio shifts to 0.50% w/v to hold the same final spore concentration. Blending is conducted in a 316L stainless steel vessel with magnetic impeller agitation at 100–150 rpm for 20–30 minutes under 2–8°C refrigeration, followed by closed transfer through a 0.22 µm vent-filtered sterile filling line into Type I glass vials. The terminal presentation is a 1.0 mL single-dose ready-to-use subcutaneous injection for bovine and bubaline prophylaxis, not a lyophilized cake. Compliance anchors for this downstream route include Ph. Eur. monograph 0371 for live anthrax spore vaccine for veterinary use, WOAH Terrestrial Manual Chapter 3.1.1, and 9 CFR 113.65 where USDA licensing is required. Batch rejection boundaries in commercial filling suites have been documented when post-dilution viable spore counts drift below the approved release specification after a 4-hour cold hold, when insufficient homogenization after glycerin addition produces visible spore agglomeration, or when filter integrity testing fails after the fill. Subcutaneous administration only is specified; intravenous or intramuscular injection is contraindicated, and concurrent prolonged antimicrobial therapy interferes with live spore replication required for protective immunity.

Why Does Lyophilized Multi-Dose Powder Require Reconstitution Volume Accuracy Below 2%?

Downstream manufacture of a lyophilized multi-dose presentation adds a controlled desiccation step that determines both field usability and regulatory release. The Strain II spore concentrate is blended with a sterilized lyoprotectant solution at a volumetric ratio of 1:1 to 1:4 spore concentrate to lyoprotectant, with total solids held at 3–5% w/v before filling. The suspension is filled into 10-dose Type I glass vials and lyophilized on a shelf freeze dryer using a cycle that ramps to −40°C, primary drying at approximately −25°C and 100 µbar chamber pressure, then secondary drying at +20°C and 50 µbar until residual moisture is below 3% by Karl Fischer titration. This moisture ceiling is critical because spore viability and cake structure degrade when secondary drying is truncated; collapse above 30°C during secondary drying has been observed on production-scale freeze dryers with poorly calibrated shelf heat transfer. The terminal finished product is a sealed lyophilized powder requiring reconstitution with a separate diluent, yielding a subcutaneous multi-dose vaccine; reconstitution volume accuracy is specified at ±2% or tighter because over-dilution alters dose-specific spore count. Compliance relies on Ph. Eur. 0371, 21 CFR 610.12 sterility testing for biological products, and EU GMP Part I Annex 2 for biological active substances; for this specific lyophilized Strain II configuration, published stability data are limited, and batch release must rely on manufacturer real-time stability protocols rather than formal compendial fixed limits.

Sheep and Goat 0.5 mL Fill-Volume Changeover on a Multi-Head Piston Filling Line

Ovine and caprine dose presentations introduce a fill-volume reduction problem that is less about spore biology and more about mechanical line changeover. If the marketing authorization specifies a 0.5 mL dose with the same minimum viable spore count per dose as the 1.0 mL cattle presentation, the API addition ratio doubles from 0.20% w/v to 0.40% w/v for a 5.0 × 10⁹ CFU/g powder to achieve 2.0 × 10⁷ CFU/mL; if the authorization defines a half-dose rather than a half-volume exception, the target spore count is reduced to 5.0 × 10⁶ CFU per dose and the blending ratio remains 0.20% w/v. The production process requires recalibrating multi-head piston filling pumps from a 1.0 mL stroke to a 0.5 mL stroke with fill tolerance of ±5%, followed by 100% in-line check weighing because small-volume vials are sensitive to piston cavitation and dose-to-dose variation. The terminal finished product is a 0.5 mL single-dose vial or a 5 mL multi-dose vial for sheep and goat flock vaccination. Experience on high-speed filling suites shows that changeover from bovine to ovine dose formats commonly creates the highest reject rate during the first 30 minutes; the acceptable process correction is to purge the line with sterile diluent, re-zero the load cell, and reject all vials outside the gravimetric warning band. Compliance references remain Ph. Eur. 0371 and WOAH Terrestrial Manual Chapter 3.1.1, with biological safety cabinet line supervision for any open filling steps if isolator transfer is not installed.

Equine anthrax vaccination in endemic and sporadic outbreak zones follows a route that differs from herd-level bovine administration mainly in pack size and injection presentation rather than spore count arithmetic. A granulated Strain II API with a certificate of analysis reading 1.2 × 10¹⁰ CFU/g is added at 0.08% w/v to a glycerin-saline stabilizer to yield 1.0 × 10⁷ CFU/mL for a 1.0 mL subcutaneous dose. The downstream process uses a closed aseptic compounding system with 0.22 µm filtration of the diluent before spore addition, followed by bubble point testing on the final filter before and after transfer into 1.0 mL cyclic olefin copolymer prefilled syringes fitted with butyl rubber plungers. Because live spore vaccines cannot be terminally sterilized by autoclaving or gamma irradiation, the entire fill path is maintained under Grade A laminar flow with active air monitoring at ≥ 1 ft³/ft²/min surface velocity. The terminal finished product is a ready-to-inject equine prefilled syringe, with a needle-attached or Luer-compatible configuration depending on regional label. Compliance references include Ph. Eur. 0371, 9 CFR 113.65, and 21 CFR 610.12. Clinical boundary conditions documented in production-scale batch records include a prohibition on intravenous or intramuscular injection, a contraindication for concurrent broad-spectrum antimicrobial therapy, and a recommended observation window of 15–30 minutes post-injection for hypersensitivity in high-value individual animals. Field veterinarians should avoid introducing air bubbles during syringe priming because bubble formation in glycerinated suspensions can cause dose volume error greater than the ±5% fill tolerance.

When Emergency Stockpile Concentrates Are Reserved in Dual-Chamber Vials

This downstream format is designed for rapid deployment rather than routine annual vaccination, and its manufacturing logic differs from single-chamber liquid or lyophilized formats. A 10× sterile spore concentrate is prepared so that chamber A contains a lyophilized cake or dense suspension equivalent to 1.0 × 10⁸ CFU per 1.0 mL concentrate, while chamber B contains 9.0 mL of sterile diluent; at the point of use, one part concentrate is mixed with nine parts diluent at a 1:9 v/v ratio to yield 1.0 × 10⁷ CFU/mL in a 10-dose reconstituted presentation. The production process requires specialized dual-chamber vial filling equipment with separate aseptic paths for spore concentrate and diluent, stopper insertion under vacuum or nitrogen, and sealing with an aluminum crimp cap without disturbing live spore viability. The terminal product type is a field-reconstitutable 10-dose subcutaneous vaccine, intended for rapid containment in anthrax outbreak zones or governmental veterinary emergency stockpiles. Compliance is anchored to Ph. Eur. 0371 and WOAH Terrestrial Manual Chapter 3.1.1, with national stockpile protocols adding real-time stability monitoring; published data for this specific dual-chamber veterinary anthrax configuration is limited, so batch release depends on manufacturer stability databases and transportation shock testing rather than a widely harmonized external standard. High-risk failure modes in this format include chamber-to-chamber seal leakage, diluent evaporation through damaged crimps, and delayed reconstitution viscosity increase when stored outside 2–8°C for extended periods.

Milling Bulk Lyophilized Strain II Cake into ≤100 µm Free-Flowing Granules

The bulk lyophilized cake can be further processed into free-flowing granules for downstream sterile suspension manufacturing when regional vaccine producers require a granular intermediate rather than a reconstituted liquid API. Milling is performed under dry nitrogen at low shear with stainless steel screens set to a nominal aperture of 100 µm; the process must avoid cake heating above 25°C because spore viability is sensitive to heat and moisture uptake. The milled granules are blended with a pre-sterilized mannitol-gelatin carrier at a 1:10 w/w ratio when the final suspension target is 1.0 × 10⁷ CFU/mL after downstream reconstitution, although the exact blend ratio is corrected against the granule certificate of analysis. The terminal product type is a granulated veterinary API intermediate for further aseptic suspension filling; it is not an oral feed premix or a tablet compression excipient. Tableting and encapsulation of live anthrax spore vaccine are contraindicated because compression shear and tablet press heat can reduce viable spore count unpredictably and fail potency release. Compliance for this granulation step follows Ph. Eur. 0371, EU GMP Part I Annex 2, and ISO cleanroom classification for particulate control in ISO 14644-1 Class 7 zones. Process validation experience indicates that the largest batch-to-batch variance arises from the residual moisture of the upstream cake; if cake moisture exceeds 3% before milling, the resulting granules tend to agglomerate and block the 100 µm sieve, while spore count per gram becomes uneven across the lot. Published data for this specific milling configuration is limited, so viability retention and particle size distribution must be treated as batch-record critical quality attributes rather than fixed compendial expectations.